Vetoquinol - Universal Registration Document - 2021

1 Vetoquinol Universal Registration Document 2020 Financial report 19 PRESENTATION OF THE GROUP Vetoquinol: an industrial Group 1.6.1 France (Lure, Tarare, Paris and Angers) The Company owns the Lure complex (Magny-Vernois). The site covers an area of nearly 16 hectares, including over 24,000 sqm of built areas (floor area), or nearly 37,000 sqm of developed area. It houses the Company’s head office, industrial activities, R&D, logistics and Group functions. Veterinary drugs and non-medicinal products for the entire global market are produced here. This unit produces sterile injectable liquids, non-sterile liquids and creams, and tablets. The Tarare plant occupies a 10,000-sqm site with two built areas totaling 4,000 sqm. Vetoquinol owns the premises. In February 2014, the Company signed a com- mercial lease for offices in Paris (located at 37 Rue de la Victoire), which house the France Department and certain Group functions. In September 2018, the Company acquired an R&D center near Angers. This site occupies an area of approximately 100 hectares of leased farming land. Classified facilities The Lure site is subject to the following provisions rela- ting to facilities classified for environmental protection (ICPE) under the dual regime of reporting and registra- tion following the revisions of the ICPE nomenclature in 2006 and 2010. The site is operated in accordance with its updated authorization order taking into account the site’s recent extensions. Lure is the subject of regular inspections by depart- ments at DREAL, most recently in late 2019. The site is not affected by the provisions of the Seveso directives. In absolute terms, all drugs and their active ingredients are liable to present environmental risks; however, the drugs manufactured by Vetoquinol do not present any specific or higher risks than the human or veterinary drugs on the market. Protection of the environment The measures taken by Vetoquinol to protect the envi- ronment are appropriate in terms of waste sorting, water consumption, the prevention of groundwater and surface water pollution, the prevention of drinking water pollu- tion, noise control and energy consumption. Tarare The Tarare plant is not subject to provisions relating to classified facilities. The products manufactured at the plant do not present any risks to the environment. Only a few raw materials, which may present a hazard under certain circums- tances, are present in small quantities at the plant. Major investments have been made in recent years in the security of the premises. This plant produces non-medicinal products mainly for the European, Asian and Canadian markets. It manufac- tures products in the form of powders, pellets, liquids, paste forms and soft chews.